Alpha-3 beta-4 nicotinic receptor
The alpha-3 beta-4 nicotinic receptor, also known as the α3β4 receptor, is a type of nicotinic acetylcholine receptor, consisting of α3 and β4 subunits.[1][2] It is located in the autonomic ganglia[3] and adrenal medulla,[4] where activation yields post- and/or presynaptic excitation.[2]
As with other nicotinic acetylcholine receptors, the α3β4 receptor is pentameric [(α3)m(β4)n where m + n = 5]. The exact subunit stoichiometry is not known and it is possible that more than one functional α3β4 receptor assembles in vivo with varying subunit stoichiometries.
Ligands
Agonists
- Acetylcholine[5] (endogenous neuromodulator that binds non-selectively to nAChRs and mAChRs.)
- Carbachol[5]
- Cytisine[5]
- Epibatidine[5]
- Nicotine[5]
- RJR-2429[6]
Antagonists
Competitive
- DHβE[5]
- compound 5, highly selective over α4β2 and α7[7]
Noncompetitive
- Dextromethorphan[8][9]
- Dextrorphan[8][9]
- Dextropropoxyphene[10]
- Hexamethonium[5]
- Imipramine, K(d) = 0.41 μM[11]
- Levacetylmethadol[10]
- Mecamylamine[5]
- Methadone[10]
- Tubocurarine[5]
- Bupropion
- Reboxetine[12]
- Ibogaine
- Voacangine
- 18-Methoxycoronaridine
- AT-1001[13]
See also
References
- ↑ Stauderman KA, Mahaffy LS, Akong M; et al. (February 1998). "Characterization of human recombinant neuronal nicotinic acetylcholine receptor subunit combinations alpha2beta4, alpha3beta4 and alpha4beta4 stably expressed in HEK293 cells". The Journal of Pharmacology and Experimental Therapeutics 284 (2): 777–89. PMID 9454827.
- 1 2 Xiao Y, Kellar KJ (July 2004). "The comparative pharmacology and up-regulation of rat neuronal nicotinic receptor subtype binding sites stably expressed in transfected mammalian cells". The Journal of Pharmacology and Experimental Therapeutics 310 (1): 98–107. doi:10.1124/jpet.104.066787. PMID 15016836.
- ↑ "Heterogeneity of nicotinic receptor class and subunit mRNA expression among individual parasympathetic neurons from rat intracardiac ganglia". J. Neurosci. (US National Library of Medicine) 17: 586–96. 1997. PMID 8987781.
- ↑ "Structural and functional diversity of native brain neuronal nicotinic receptors.". Biochem. Pharmacol. (US National Library of Medicine) 78: 703–11. 2009. doi:10.1016/j.bcp.2009.05.024. PMID 19481063.
- 1 2 3 4 5 6 7 8 9 Xiao Y, Meyer EL, Thompson JM, Surin A, Wroblewski J, Kellar KJ (August 1998). "Rat alpha3/beta4 subtype of neuronal nicotinic acetylcholine receptor stably expressed in a transfected cell line: pharmacology of ligand binding and function". Molecular Pharmacology 54 (2): 322–33. PMID 9687574.
- ↑ Bencherif, M.; Schmitt, J. D.; Bhatti, B. S.; Crooks, P.; Caldwell, W. S.; Lovette, M. E.; Fowler, K.; Reeves, L.; Lippiello, P. M. (1998). "The heterocyclic substituted pyridine derivative (+/-)-2-(-3-pyridinyl)-1-azabicyclo2.2.2octane (RJR-2429): A selective ligand at nicotinic acetylcholine receptors". The Journal of Pharmacology and Experimental Therapeutics 284 (3): 886–894. PMID 9495846.
- ↑ Zaveri NT (2011). "The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications". Curr Top Med Chem 11 (9): 1151–6. doi:10.2174/156802611795371341. PMID 21050175.
- 1 2 Hernandez SC, Bertolino M, Xiao Y, Pringle KE, Caruso FS, Kellar KJ (2000). "Dextromethorphan and its metabolite dextrorphan block alpha3beta4 neuronal nicotinic receptors". J. Pharmacol. Exp. Ther. 293 (3): 962–7. PMID 10869398.
- 1 2 Damaj MI, Flood P, Ho KK, May EL, Martin BR (February 2005). "Effect of dextrometorphan and dextrorphan on nicotine and neuronal nicotinic receptors: in vitro and in vivo selectivity". The Journal of Pharmacology and Experimental Therapeutics 312 (2): 780–5. doi:10.1124/jpet.104.075093. PMID 15356218.
- 1 2 3 "Blockade of Rat α3β4 Nicotinic Receptor Function by Methadone, Its Metabolites, and Structural Analogs — JPET".
- ↑ Arias HR, Targowska-Duda KM, Feuerbach D, Sullivan CJ, Maciejewski R, Jozwiak K (March 2010). "Different interaction between tricyclic antidepressants and mecamylamine with the human alpha3beta4 nicotinic acetylcholine receptor ion channel". Neurochem. Int. 56 (4): 642–9. doi:10.1016/j.neuint.2010.01.011. PMID 20117161.
- ↑ Miller, DK; Wong, EH; Chesnut, MD; Dwoskin, LP (Aug 2002). "Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors.". The Journal of Pharmacology and Experimental Therapeutics 302 (2): 687–95. doi:10.1124/jpet.302.2.687. PMID 12130733.
- ↑ Toll, L.; Zaveri, N. T.; Polgar, W. E.; Jiang, F.; Khroyan, T. V.; Zhou, W.; Xie, X. (S.); Stauber, G. B.; Costello, M. R.; Leslie, F. M. (2012). "AT-1001: A High Affinity and Selective α3β4 Nicotinic Acetylcholine Receptor Antagonist Blocks Nicotine Self-Administration in Rats". Neuropsychopharmacology 37 (6): 1367–1376. doi:10.1038/npp.2011.322. PMC 3327842. PMID 22278092.
|
This article is issued from Wikipedia - version of the Monday, March 21, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.